These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 12012149)

  • 1. Incidence and determinants of migraine prophylactic medication in the Netherlands.
    Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC
    Eur J Clin Pharmacol; 2002 May; 58(2):149-55. PubMed ID: 12012149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy--a pilot study.
    Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC
    Pharmacoepidemiol Drug Saf; 2004 Jan; 13(1):41-7. PubMed ID: 14971122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migraine prophylactic medication usage patterns in The Netherlands.
    Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC
    Cephalalgia; 2003 May; 23(4):293-301. PubMed ID: 12716348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of specific antimigraine drug use--a study based on the records of 18 community pharmacies.
    Lohman JJ; van der Kuy-de Ree MM;
    Cephalalgia; 2005 Mar; 25(3):214-8. PubMed ID: 15689197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting.
    Yaldo AZ; Wertz DA; Rupnow MF; Quimbo RM
    Clin Ther; 2008 Dec; 30(12):2452-60. PubMed ID: 19167603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and determinants of antidepressant drug use in migraine patients.
    Rahimtoola H; Buurma H; Tijssen CC; Leufkens HG; Egberts AC
    Int Clin Psychopharmacol; 2003 Nov; 18(6):331-9. PubMed ID: 14571153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of ischemic complications related to the intensity of triptan and ergotamine use.
    Wammes-van der Heijden EA; Rahimtoola H; Leufkens HG; Tijssen CC; Egberts AC
    Neurology; 2006 Oct; 67(7):1128-34. PubMed ID: 17030745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of ergotamine and sumatriptan use in the Netherlands from 1991 to 1997.
    Rahimtoola H; Egberts AC; Buurma H; Tijssen CC; Leufkens HG
    Cephalalgia; 2001 Jun; 21(5):596-603. PubMed ID: 11472386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prophylactic treatments of migraine].
    Massiou H
    Rev Neurol (Paris); 2000; 156 Suppl 4():4S79-86. PubMed ID: 11139754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002.
    Mirandola M; Andretta M; Corbari L; Sorio A; Nosè M; Barbui C
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):412-20. PubMed ID: 16287199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine Prophylaxis and Acute Treatment Patterns Among Commercially Insured Patients in the United States.
    Woolley JM; Bonafede MM; Maiese BA; Lenz RA
    Headache; 2017 Oct; 57(9):1399-1408. PubMed ID: 28842990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nebivolol and metoprolol for treating migraine: an advance on beta-blocker treatment?
    Schellenberg R; Lichtenthal A; Wöhling H; Graf C; Brixius K
    Headache; 2008 Jan; 48(1):118-25. PubMed ID: 18184294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute migraine treatment: patterns of use and satisfaction in a clinical population.
    Malik SN; Hopkins M; Young WB; Silberstein SD
    Headache; 2006 May; 46(5):773-80. PubMed ID: 16643580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes.
    Bigal ME; Rapoport AM; Sheftell FD; Tepper SJ; Lipton RB
    Cephalalgia; 2004 Jun; 24(6):483-90. PubMed ID: 15154858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of adherence to triptans: factors of sustained vs lapsed users.
    Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
    Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy of migraine].
    Pfaffenrath V; Reiter M
    Wien Med Wochenschr; 1988 Dec; 138(23-24):591-9. PubMed ID: 2906193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment choices and patterns in migraine patients with and without a cardiovascular risk profile.
    Wammes-van der Heijden EA; Tijssen CC; Egberts AC
    Cephalalgia; 2009 Mar; 29(3):322-30. PubMed ID: 19220314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of diagnosis and treatment of migraine.
    Silberstein SD; Lipton RB
    Neurology; 1994 Oct; 44(10 Suppl 7):S6-16. PubMed ID: 7969947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence with migraine prophylaxis in clinical practice.
    Berger A; Bloudek LM; Varon SF; Oster G
    Pain Pract; 2012 Sep; 12(7):541-9. PubMed ID: 22300068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.